Three-drug combination for advanced colorectal cancer spread to the liver
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of three drugs (tislelizumab, fruquintinib, and chidamide) for colorectal cancer that has spread to the liver and has not responded to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old
- Have colorectal cancer that has spread to your liver
- Have had cancer that progressed after treatment with standard chemotherapies (including drugs like fluorouracil, oxaliplatin, irinotecan)
- Be in generally good health (able to care for yourself, reasonable blood counts and organ function)
- Must not have been previously treated with certain immunotherapy or HDAC inhibitor drugs, or irinotecan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a combination of two drugs and a liver-directed therapy for people with advanced colorectal cancer that has spread to the liver. It aims to see if this approach can help when standard first-line treatment has stopped working.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. The drugs may help your immune system fight the cancer and block its growth.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.